A Single-Center Retrospective Comparative Study of Conventional and Accelerated Fractionated Radiotherapy for Early-Stage Laryngeal Cancer.

A Single-Center Retrospective Comparative Study of Conventional and Accelerated Fractionated Radiotherapy for Early-Stage Laryngeal Cancer.

Publication date: Aug 01, 2025

Radiotherapy is widely used in the treatment of early-stage laryngeal cancer (stage I and II). We analyzed the efficacy of conventional and accelerated fractionated radiotherapy (52. 5 Gy in 16 fractions) for early-stage laryngeal cancer retrospectively. We compared the outcomes of 25 patients treated with conventional fractionation (CF group: 66-70 Gy in 33-35 fractions) and 20 patients treated with accelerated fractionation (AF group: 52. 5 Gy in 16 fractions) radiotherapy from 2011 to 2024 at our institution. Local control rate was 87. 8% at five years in the CF group and 95% at five years in the AF group. Acute adverse events were significantly higher in the CF group, with 72% Grade 2 or higher dermatitis compared to 20% in the AF group (p

Open Access PDF

Concepts Keywords
Cancer accelerated fractionation radiotherapy
Early altered fractionation radiotherapy
Laryngeal conventional radiotherapy
Pandemic laryngeal cancer
Radiotherapy moderate hypofractionation

Semantics

Type Source Name
disease MESH Laryngeal Cancer
disease MESH dermatitis
disease MESH COVID-19 pandemic
drug DRUGBANK Tropicamide
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH malignancy
drug DRUGBANK Methionine
disease MESH squamous carcinoma
disease MESH metastasis
disease IDO algorithm
disease IDO process
disease MESH death
disease MESH recurrence
disease MESH mucositis
drug DRUGBANK L-Aspartic Acid
disease MESH Renal failure
disease MESH COPD
disease MESH bleeding
disease MESH Dysphagia
drug DRUGBANK Morphine
disease MESH complications
disease MESH prostate cancers
disease MESH laryngeal edema
disease MESH necrosis
disease MESH sclerosis
disease IDO susceptibility
disease MESH carcinoma
disease MESH neck cancers
disease MESH arc
drug DRUGBANK 3 7 11 15-Tetramethyl-Hexadecan-1-Ol
disease MESH breast cancer
pathway KEGG Breast cancer

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *